Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 537.00 | |
200 mg | In stock | $ 768.00 | |
500 mg | In stock | $ 1,150.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases. |
In vitro | PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) [1]. |
In vivo | Administering PF-1355 orally diminishes MPO activity in plasma, lessens vascular edema and neutrophil recruitment, and increases circulating cytokines levels. PF-1355 treatment entirely inhibits albuminuria and chronic renal dysfunction in a model of anti-glomerular basement membrane disease [1]. |
Synonyms | PF-06281355, PF 06281355, ZINC205721785 |
Molecular Weight | 321.35 |
Formula | C14H15N3O4S |
CAS No. | 1435467-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL (124.5 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-1355 1435467-38-1 Metabolism Glutathione Peroxidase PF 1355 PF-06281355 PF 06281355 ZINC 205721785 PF1355 PF06281355 ZINC205721785 ZINC-205721785 inhibitor inhibit